News & Updates

Phase II data presented at CROI 2024 demonstrated the ability of an investigational, long-acting, oral once-weekly regimen comprising islatravir, a nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class capsid inhibitor, to maintain viral suppression at week 24 in virologically suppressed people living with HIV (PWH).

Adverse childhood experiences (ACEs) are associated with depression, anxiety, substance use disorder, and stress-related disorders in adulthood, a twin cohort study has shown.

Patients with complicated urinary tract infection (UTI) may fare better with cefepime–taniborbactam than with meropenem, with the combination having been associated with much higher treatment success rates in the phase III CERTAIN-1 trial.

A negative affective state can aggravate dyspnoea in patients with chronic obstructive pulmonary disease (COPD), a study has shown. This suggests that reducing the likelihood of negative mood or improving the mood can help in managing morbidities associated with dyspnoea in COPD.